blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2654773

EP2654773 - GLUCAGON ANALOGS EXHIBITING GIP RECEPTOR ACTIVITY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.08.2019
Database last updated on 17.07.2024
FormerThe patent has been granted
Status updated on  31.08.2018
FormerGrant of patent is intended
Status updated on  19.04.2018
FormerExamination is in progress
Status updated on  06.03.2017
Most recent event   Tooltip03.07.2020Lapse of the patent in a contracting state
New state(s): CY, MK		published on 05.08.2020  [2020/32]
Applicant(s)For all designated states
Indiana University Research and Technology Corporation
518 Indiana Avenue
Indianapolis, IN 46202 / US
[2017/25]
Former [2013/44]For all designated states
Indiana University Research and Technology Corporation
351 West 10th Street
Indianapolis, IN 46202 / US
Inventor(s)01 / DIMARCHI, Richard, D.
10890 Wilmington Drive
Carmel IN 46033 / US
02 / WARD, Brian
2406 Grant Blvd.
Lebanon IN 46052 / US
 [2013/44]
Representative(s)Ponti & Partners, S.L.P
Edifici PRISMA
Av. Diagonal núm. 611-613, Planta 2
08028 Barcelona / ES
[N/P]
Former [2018/40]Ponti & Partners, S.L.P
C. de Consell de Cent 322
08007 Barcelona / ES
Former [2013/44]Oficina Ponti, SLP
C. Consell de Cent, 322
08007 Barcelona / ES
Application number, filing date11808086.020.12.2011
[2018/40]
WO2011US66164
Priority number, dateUS201161514609P03.08.2011         Original published format: US 201161514609 P
US201061426285P22.12.2010         Original published format: US 201061426285 P
[2013/44]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2012088116
Date:28.06.2012
Language:EN
[2012/26]
Type: A2 Application without search report 
No.:EP2654773
Date:30.10.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 28.06.2012 takes the place of the publication of the European patent application.
[2013/44]
Type: B1 Patent specification 
No.:EP2654773
Date:03.10.2018
Language:EN
[2018/40]
Search report(s)International search report - published on:EP15.11.2012
ClassificationIPC:C07K14/605, A61K38/00
[2018/17]
CPC:
C07K14/605 (EP,KR,US); A61K38/26 (KR); A61P1/00 (EP);
A61P1/14 (EP); A61P25/02 (EP); A61P3/04 (EP);
A61P3/10 (EP); A61P43/00 (EP); A61K38/00 (EP,US) (-)
Former IPC [2013/44]A61K38/26
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/44]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:GLOCAGONANALOGA MIT GIP-REZEPTORAKTIVITÄT[2013/44]
English:GLUCAGON ANALOGS EXHIBITING GIP RECEPTOR ACTIVITY[2013/44]
French:ANALOGUES DU GLUCAGON PRÉSENTANT UNE ACTIVITÉ DE RÉCEPTEUR DE GIP[2013/44]
Entry into regional phase03.07.2013National basic fee paid 
03.07.2013Designation fee(s) paid 
03.07.2013Examination fee paid 
Examination procedure03.07.2013Examination requested  [2013/44]
10.02.2014Amendment by applicant (claims and/or description)
14.03.2016Despatch of a communication from the examining division (Time limit: M04)
17.05.2016Reply to a communication from the examining division
23.02.2017Despatch of a communication from the examining division (Time limit: M06)
08.08.2017Reply to a communication from the examining division
22.01.2018Despatch of a communication from the examining division (Time limit: M02)
05.03.2018Reply to a communication from the examining division
20.04.2018Communication of intention to grant the patent
16.08.2018Fee for grant paid
16.08.2018Fee for publishing/printing paid
16.08.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  14.03.2016
Opposition(s)04.07.2019No opposition filed within time limit [2019/37]
Fees paidRenewal fee
27.12.2013Renewal fee patent year 03
29.12.2014Renewal fee patent year 04
28.12.2015Renewal fee patent year 05
27.12.2016Renewal fee patent year 06
27.12.2017Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU20.12.2011
AL03.10.2018
AT03.10.2018
CY03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
MK03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
RS03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
SM03.10.2018
TR03.10.2018
IE20.12.2018
LU20.12.2018
MT20.12.2018
BE31.12.2018
CH31.12.2018
LI31.12.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
[2020/31]
Former [2020/30]HU20.12.2011
AL03.10.2018
AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
RS03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
SM03.10.2018
TR03.10.2018
IE20.12.2018
LU20.12.2018
MT20.12.2018
BE31.12.2018
CH31.12.2018
LI31.12.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2020/17]AL03.10.2018
AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
RS03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
SM03.10.2018
TR03.10.2018
IE20.12.2018
LU20.12.2018
MT20.12.2018
BE31.12.2018
CH31.12.2018
LI31.12.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2020/08]AL03.10.2018
AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
RS03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
SM03.10.2018
IE20.12.2018
LU20.12.2018
MT20.12.2018
BE31.12.2018
CH31.12.2018
LI31.12.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2020/04]AL03.10.2018
AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
RS03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
SM03.10.2018
IE20.12.2018
LU20.12.2018
BE31.12.2018
CH31.12.2018
LI31.12.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/50]AL03.10.2018
AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
RS03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
SM03.10.2018
IE20.12.2018
LU20.12.2018
BE31.12.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/48]AL03.10.2018
AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
RS03.10.2018
SE03.10.2018
SK03.10.2018
SM03.10.2018
IE20.12.2018
LU20.12.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/40]AL03.10.2018
AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
RS03.10.2018
SE03.10.2018
SK03.10.2018
SM03.10.2018
LU20.12.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/39]AL03.10.2018
AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
RS03.10.2018
SE03.10.2018
SK03.10.2018
SM03.10.2018
LU20.12.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/37]AL03.10.2018
AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
RS03.10.2018
SE03.10.2018
SM03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/34]AL03.10.2018
AT03.10.2018
CZ03.10.2018
DK03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
PL03.10.2018
RS03.10.2018
SE03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/26]AL03.10.2018
AT03.10.2018
CZ03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
PL03.10.2018
RS03.10.2018
SE03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/25]AT03.10.2018
CZ03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
PL03.10.2018
RS03.10.2018
SE03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
Former [2019/24]AT03.10.2018
CZ03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
PL03.10.2018
SE03.10.2018
BG03.01.2019
NO03.01.2019
GR04.01.2019
IS03.02.2019
Former [2019/23]AT03.10.2018
CZ03.10.2018
FI03.10.2018
HR03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
PL03.10.2018
BG03.01.2019
NO03.01.2019
IS03.02.2019
Former [2019/22]CZ03.10.2018
FI03.10.2018
LT03.10.2018
NL03.10.2018
PL03.10.2018
BG03.01.2019
NO03.01.2019
IS03.02.2019
Former [2019/21]FI03.10.2018
LT03.10.2018
NL03.10.2018
NO03.01.2019
IS03.02.2019
Former [2019/20]LT03.10.2018
NL03.10.2018
NO03.01.2019
Former [2019/17]NL03.10.2018
Cited inInternational search[A]WO2008101017  (INDIANA UNVERSITY RES AND TECH [US], et al) [A] 92,94,104-135 * Invention 15 + 17 * * claim 65 * * sequence 495 *;
 [X]WO2009155257  (UNIV INDIANA RES & TECH CORP [US], et al) [X] 1-6,14-51,104-136 * Invention 1 * * page 6, line 10 - page 9, line 5 * * page 113; table 8 * * claims 1-96 *;
 [X]WO2010071807  (UNIV INDIANA RES & TECH CORP [US], et al) [X] 7-61,104-136 * Invention 2 + 3 * * page 49, line 27 - page 51, line 6 * * page 59, line 8 - page 60, line 22 * * page 66, line 15 - page 67, line 5 *;
 [I]  - PAN CLARK Q ET AL, "Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC, US, vol. 281, no. 18, doi:10.1074/JBC.M600127200, ISSN 0021-9258, (20060501), pages 12506 - 12515, (20060227), XP002529523 [I] 1-6,14-51,104-136 * abstract * * page 12506, paragraph 3 - page 12507, paragraph 3 * * page 12508; table 1 * * page 12511; table 3 * * page 12513, paragraph 2 - paragraph 3 *

DOI:   http://dx.doi.org/10.1074/jbc.m600127200
 [I]  - PENGYUN LI ET AL, "Design, synthesis and crystallization of a novel glucagon analog as a therapeutic agent", ACTA CRYSTALLOGRAPHICA SECTION F STRUCTURAL BIOLOGY AND CRYSTALLIZATION COMMUNICATIONS, (20070701), vol. 63, no. 7, doi:10.1107/S1744309107028655, ISSN 1744-3091, pages 599 - 601, XP055010072 [I] 52-61,104-136 * Invention 3 * * abstract * * page 600; figure 1 *

DOI:   http://dx.doi.org/10.1107/S1744309107028655
 [A]  - "Enhanced potency exhibiting modified human GLP-1 peptide SEQ ID:495.", Geneseq, (20081127), Database accession no. ATD14223, URL: EBI, XP002679991 [A] 92,94,104-136 * sequence . *
 [A]  - CHABENNE JOSEPH R ET AL, "Optimization of the native glucagon sequence for medicinal purposes.", JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY NOV 2010 LNKD- PUBMED:21129326, (201011), vol. 4, no. 6, ISSN 1932-2968, pages 1322 - 1331, XP007920819 [A] 92,94,104-136 * abstract * * page 1327, column r, paragraph 2 - page 1328, column r, paragraph 1 * * figure 5 * * page 1330, column r, paragraph 2 * * table 1 *

DOI:   http://dx.doi.org/10.1177/193229681000400605
by applicantUS4450150
 WO8705330
 US5087616
 US5449752
 WO9940942
 WO0032218
 WO2004033036
 WO2007133747
 WO2007141411
 US7355008
 US7381408
 WO2008101017
 WO2008130158
 US2008286808
 WO2009023270
 WO2010011439
 WO2010071807
 WO2010148089
 WO2011094337
    - FLEGAL ET AL., JAMA, (2010), vol. 303, no. 3, pages 235 - 241
    - NAUCK ET AL., J. CLIN. ENDOCRINOL. METAB., (1993), vol. 76, pages 912 - 917
    - IRWIN ET AL., REGUL. PEPT., (2009), vol. 153, pages 70 - 76
    - MILLER, BIOCHEM BIOPHYS RES COMMUN, (1996), vol. 218, pages 377 - 382
    - SHIMOHIGASHI; STAMMER, INT J PEPT PROTEIN RES, (1982), vol. 19, pages 54 - 62
    - PREVIERO ET AL., BIOCHIM BIOPHYS ACTA, (1972), vol. 263, pages 7 - 13
    - SAN; SILVIUS, J PEPT RES, (2005), vol. 66, pages 169 - 180
    - "Chemical Modifications of Proteins: History and Applications", BIOCONJUGATE CHEM., (1990), vol. 1, pages 2 - 12
    - HASHIMOTO ET AL., "Synthesis of Palmitoyl Derivatives of Insulin and their Biological Activity", PHARMACUETICAL RES., (1989), vol. 6, no. 2, doi:doi:10.1023/A:1015992828666, pages 171 - 176, XP002050607

DOI:   http://dx.doi.org/10.1023/A:1015992828666
    - LYU ET AL., PROC NATL ACAD SCI U.S.A., (1991), vol. 88, pages 5317 - 5320
    - HOUSTON, JR. ET AL., J PEPTIDE SCI, (2004), vol. 1, pages 274 - 282
    - SHEEHAN ET AL., J AM CHEM SOC, (1973), vol. 95, pages 875 - 879
    - SCHAFMEISTER ET AL., J. AM. CHEM. SOC., (2000), vol. 122, pages 5891 - 5892
    - WALENSKY ET AL., SCIENCE, (2004), vol. 305, pages 1466 - 1470
    - BLACKWELL ET AL., ANGEW, CHEM., INT. ED., (1998), vol. 37, pages 3281 - 3284
    - MATTEUCCI ET AL., TETRAHEDRON LETTERS, (2004), vol. 45, pages 1399 - 1401
    - MAYER ET AL., J. PEPTIDE RES., (1998), vol. 51, pages 432 - 436
    - POLINSKY ET AL., J. MED. CHEM., (1992), vol. 35, pages 4185 - 4194
    - OSAPAY ET AL., J. MED. CHEM., (1997), vol. 40, pages 2241 - 2251
    - FUKASE ET AL., BULL. CHEM..SOC. JPN., (1992), vol. 65, pages 2227 - 2240
    - HARPP ET AL., J. ORG. CHEM., (1971), vol. 36, pages 73 - 80
    - GOODMAN; SHAO, PURE APPL. CHEM., (1996), vol. 68, pages 1303 - 1308
    - OSAPAY; GOODMAN, J. CHEM. SOC. CHEM. COMMUN., (1993), pages 1599 - 1600
    - PHELAN ET AL., J. AM. CHEM. SOC., (1997), vol. 119, pages 455 - 460
    - JACKSON ET AL., J. AM. CHEM. SOC., (1991), vol. 113, pages 9391 - 9392
    - RUDINGER; JOST, EXPERIENTIA, (1964), vol. 20, pages 570 - 571
    - ANDREWS; TABOR, TETRAHEDRON, (1999), vol. 55, pages 11711 - 11743
    - GHADIRI ET AL., J. AM. CHEM. SOC., (1990), vol. 112, pages 1630 - 1632
    - GHADIRI ET AL., J. AM. CHEM. SOC., (1997), vol. 119, pages 9063 - 9064
    - DAVIES, J. PEPTIDE. SCI., (2003), vol. 9, pages 471 - 501
    - PASCHEK ET AL., PROC NATL ACAD SCI USA, (2008), vol. 105, no. 46, pages 17754 - 17759
    - H. S. SAWHNEY; C. P. PATHAK; J. A. HUBBELL, MACROMOLECULES, (1993), vol. 26, pages 581 - 587
    - T. E. CREIGHTON, Proteins: Structure and Molecular Properties, W.H. FREEMAN & CO., (1983), pages 79 - 86
    - WRISTON, CRC CRIT. REV. BIOCHEM., (1981), pages 259 - 306
    - BURMEISTER ET AL., NATURE, (1994), vol. 372, page 379
    - SONDERMANN ET AL., NATURE, (2000), vol. 406, pages 267 - 273
    - HENRY ET AL., BIOCHEMISTRY, (1997), vol. 36, pages 15568 - 15578
    - LEWIS ET AL., J IMMUNOL., (2005), vol. 175, pages 6694 - 701
    - SAYERS ET AL., J BIOL CHEM., (2004), vol. 279, no. 34, pages 35320 - 5
    - SHIELDS ET AL., J. BIOL. CHEM., (2001), vol. 276, page 6591
    - ROUTLEDGE ET AL., TRANSPLANTATION, (1995), vol. 60, page 847
    - FRIEND ET AL., TRANSPLANTATION, (1999), vol. 68, page 1632
    - SHIELDS ET AL., J. BIOL. CHEM., (1995), vol. 276, page 6591
    - WARD; GHETIE, THERAPEUTIC IMMUNOLOGY, (1995), vol. 2, page 77
    - ARMOUR ET AL., EUR. J. IMMUNOL., (1999), vol. 29, page 2613
    - KINSTLER ET AL., ADV. DRUG. DELIVERY REV., (2002), vol. 54, pages 477 - 485
    - ROBERTS ET AL., ADV. DRUG DELIVERY REV., (2002), vol. 54, pages 459 - 476
    - ZALIPSKY ET AL., ADV. DRUG DELIVERY REV., (1995), vol. 16, pages 157 - 182
    - QIAN ET AL., INT J PHARM, (2009), vol. 366, pages 218 - 220
    - ADJEI; GARREN, PHARMACEUTICAL RESEARCH, (1990), vol. 7, no. 6, pages 565 - 569
    - KAWASHIMA ET AL., J CONTROLLED RELEASE, (1999), vol. 62, no. 1-2, pages 279 - 287
    - LIU ET AL., PHARM RES, (1993), vol. 10, no. 2, pages 228 - 232
    - BANKER AND CHALMERS,, Pharmaceutics and Pharmacy Practice, J. B. LIPPINCOTT COMPANY, (1982), pages 238 - 250
    - TOISSEL, ASHP Handbook on Injeciable Drugs, 4th ed.,, (1986), pages 622 - 630
    - WADHWA ET AL., J DRUG TARGETING, (1995), vol. 3, pages 111 - 127
    - QIAN ET AL., J PHARM, (2009), vol. 374, pages 46 - 52
    - LTEIF; MATHER, CAN. J. CARDIOL., (2004), vol. 20, no. B, pages 66B - 76B
    - WORMAN, HOWARD J., Alcoholic Liver Disease, COLUMBIA UNIVERSITY MEDICAL CENTER
    - SCHNOLZER ET AL., INT. J. PEPTIDE PROTEIN RES., (1992), vol. 40, pages 180 - 193
    - SCHNOLZER ET AL., J. PEPTIDE PROTEIN RES., (1992), vol. 40, pages 180 - 193
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.